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Abstract 23 
 24 
Retinal pigment epithelium (RPE) is a major part of blood-retinal barrier that affects drug elimination from the 25 
vitreous to the blood and drug distribution from blood circulation into the eye. Even though drug clearance from 26 
the vitreous has been well studied, the role of RPE in the process has not been quantified. The aim of this work 27 
was to study the role of RPE clearance (CLRPE) as part of drug elimination from the vitreous and ocular drug 28 
distribution from the systemic blood circulation. We determined the bidirectional permeability of eight small 29 
molecular weight drugs and bevacizumab antibody across isolated bovine RPE-choroid. Permeability of small 30 
molecules was 10-6 – 10-5 cm/s showing 13-15 fold range of outward and inward permeation, while permeability of 31 
bevacizumab was lower by 2-3 orders of magnitude. Most small molecular weight drugs showed comparable 32 
outward (vitreous-to-choroid) and inward (choroid-to-vitreous) permeability across the RPE-choroid, except 33 
ciprofloxacin and ketorolac that had an over 6 and 14-fold higher outward than inward permeability, respectively, 34 
possibly indicating active transport. Six of seven tested small molecular weight drugs had outward CLRPE values 35 
that were comparable with their intravitreal clearance (CLIVT) values (0.84-2.6 fold difference). On the contrary, 36 
bevacizumab had an outward CLRPE that was only 3.5% of the CLIVT, proving that its main route of elimination 37 
(after intravitreal injection) is not RPE permeation. Experimental values were used in pharmacokinetic simulations 38 
to assess the role of the RPE in drug transfer from the systemic blood circulation to the vitreous (CLBV). We 39 
conclude that for small molecular weight drugs the RPE is an important route in drug transfer between the vitreal 40 
cavity and blood, whereas it effectively hinders the movement of bevacizumab from the vitreous to the systemic 41 
circulation. 42 
 43 
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1. Introduction 44 
 45 
The prevalence of age-related diseases at the back of the eye, such as age-related macular degeneration (AMD), 46 
diabetic retinopathy, glaucoma and macular edema is constantly growing. The diseases with neovascular 47 
changes, such as exudative AMD are treated with anti-VEGF compounds, such as Fab-fragment ranibizumab 48 
(Lucentis®), soluble receptor aflibercept (Eylea®), and antibody bevacizumab (off-label use of Avastin®). Other 49 
potential drugs for the treatment of neovascularization include tyrosine kinase inhibitors, aptamers, and siRNA 1. 50 
Inflammations associated with diabetic macular edema, AMD, and uveitis, are treated with corticosteroids, such 51 
as triamcinolone acetonide and dexamethasone 2. Drug treatment of these diseases is accomplished with 52 
intravitreal administration of drug solutions, suspensions or implants. Even though intravitreal injections are 53 
invasive they are the method-of-choice in the retinal drug treatment, because topical, subconjunctival and systemic 54 
drug administrations do not provide adequate drug delivery to the retina 3.    55 
 56 
After an intravitreal injection, the drug diffuses in the vitreous humour and distributes to the neighboring tissues. 57 
All drugs are capable of diffusing from the vitreous to the anterior chamber and then eliminate from the eye via 58 
aqueous humor outflow 4. Additionally, the drugs may be eliminated from the vitreous posteriorly, across the blood-59 
ocular barriers, if the compound has adequate membrane permeability based on its molecular properties (e.g. 60 
size, lipophilicity) 5. Blood-ocular barriers include two main components: blood-aqueous barrier (BAB) and blood-61 
retinal barrier (BRB). The BRB consists of retinal pigment epithelium (RPE) and the endothelium of the retinal 62 
vessels, whereas the BAB is formed by the posterior iris epithelium, iridial capillaries, ciliary muscle capillaries, 63 
and nonpigmented ciliary epithelium. Inter-cellular tight-junctions are found both in the BAB and the BRB, limiting 64 
the size of the paracellular space to about 2 nm (diameter) and restricting the molecular transfer between the eye 65 
and blood circulation 3,6.  66 
 67 
The RPE is situated between the retinal photoreceptors and choroid, and it is essential for the function of the 68 
retina, maintaining the homeostasis between the neural retina and blood circulation of the fenestrated choroidal 69 
blood vessels. Due to its large surface area, the RPE is considered to be an important route of elimination of small 70 
molecular weight drugs 3. After crossing the neural retina and RPE, the choroid acts as an eliminating sink, 71 
because the leaky choroidal vessels have high blood flow. Small molecules may cross the RPE transcellularly and 72 
paracellularly, and they have wide range of intravitreal clearance values (0.031 – 1.530 ml/h) 5 that depend on the 73 
ability of the compounds to permeate across the blood ocular barriers. Due to their poor permeation of the BRB, 74 
intravitreally injected proteins and other macromolecules are mainly eliminated from the vitreous to the aqueous 75 
humor outflow, resulting in low intravitreal clearance values of 0.011 – 0.071 ml/h 5. In principle, drugs may cross 76 
the RPE by passive permeation and/or active transport, depending on drug concentration, expression and 77 
localization of transporters, and affinity of drug to the transporter protein. So far, evidence suggests that passive 78 
permeability is the main mechanism of drug clearance across the BRB. Recently, the RPE transporters were 79 
quantitated 7,8, but the clinical role of RPE transporters is still unclear 9. 80 
 81 
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The knowledge of the intravitreal pharmacokinetics is important in order to develop efficient retinal drug treatments 82 
as intravitreal injections or implants 5. Furthermore, drug permeability in the BRB is a key parameter in defining 83 
distribution of drugs from the blood circulation to the posterior eye segment 10. A reliable quantitative structure-84 
property relationship model (QSPR) was developed for clearance of small molecular weight drugs between 85 
vitreous and blood circulation 5. However, intravitreal clearance values do not provide information about the routes 86 
of vitreal drug elimination. Previously, permeability of some β-blocking agents and FITC-dextrans were 87 
investigated in isolated bovine RPE-choroid 11, which demonstrated the effects of the molecular size and 88 
lipophilicity (logD7.4) on permeability. In this study, we extended this approach to eight small molecular weight 89 
drugs and one protein drug, bevacizumab (Avastin ®). To our understanding RPE permeability for such drug set 90 
(with broad lipophilicity and molecular weight range) has not been previously reported in the literature. The 91 
experimental permeability values and in vivo intravitreal clearance values from rabbits were used to estimate the 92 
role of the RPE as intravitreal route of drug elimination and distribution route from the systemic blood circulation.  93 
 94 
2. Materials and Methods 95 
 96 
2.1 Drug molecules 97 
 98 
Eight small molecular weight drugs and one protein drug were chosen for the permeability study (Table 1). The 99 
cassette mixture of the small molecular weight drugs was prepared by combining the individual stock solutions 100 
(Table 1) and diluting with a balanced salt solution BSS Plus (Alcon Laboratories, TX, USA) containing 7.14  mg/ml 101 
sodium chloride,  0.38  mg/ml  potassium  chloride, 0.154  mg/ml  calcium  chloride  dihydrate,  0.2  mg/ml 102 
magnesium  chloride hexahydrate, 0.42  mg/ml, dibasic  sodium  phosphate,  2.1  mg/ml sodium  bicarbonate, 103 
0.92  mg/ml dextrose, 0.184  mg/ml glutathione  disulfide, and supplemented with 10 mM Hepes (pH 7.4). The 104 
drug concentration in the cassette mixture stock solution was either 20 or 200 µg/ml, depending on the analytical 105 
limit of quantification. The concentrations of aztreonam, ganciclovir, and quinidine were 200 µg/ml, whereas the 106 
other compounds were used at concentration of 20 µg/ml.   107 
 108 
 109 
 110 
 111 
 112 
 113 
 114 
 115 
 116 
 117 
 118 
 119 
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Table 1. Drug molecules in the permeability study.  120 
Drug molecules Stock solution Manufacturer 
Aztreonam 10 mg/ml in DMSO Fluka, China 
Ciprofloxacin 0.5 mg/ml in 0.1 M HCl BioChemica, China 
Fluconazole 10 mg/ml in DMSO Sigma-Aldrich, St.Louis, MO, USA 
Ganciclovir 10 mg/ml in DMSO Sigma-Aldrich, St.Louis, MO, USA 
Ketorolac Tris salt 1 mg/ml in PBS Sigma-Aldrich, St.Louis, MO, USA 
Methotrexate 1 mg/ml in DMSO Fluka, USA 
Quinidine 10 mg/ml in DMSO Sigma-Aldrich, Steinheim, Germany 
Voriconazole 10 mg/ml in DMSO Fluka, Steinheim, Germany 
Bevacizumab Avastin® 25 mg/ml Roche Pharma AG, Grenzach-Wyhlen, Germany 
 121 
 122 
2.2 Tissue preparation 123 
 124 
Freshly enucleated bovine eyes (> 1 year old animals) were obtained from a local slaughterhouse and delivered 125 
to the lab in CO2 Independent Medium (Gibco, Life Technologies). The eyes were first cleaned of muscle and fat 126 
tissue surrounding the eye. Then the anterior part of the eye was removed by cutting circumferentially 127 
approximately 8 mm posterior from the limbus. The vitreous was gently removed from the remaining eye cup that 128 
was cut in three parts. Medium was added on the tissues to avoid drying. The neural retina was gently removed 129 
using forceps and, thereafter, the RPE-choroid was carefully isolated from sclera using scissors and curved 130 
forceps, avoiding the area of the optic nerve.  131 
 132 
2.3 Permeability study 133 
 134 
The isolated RPE-choroid was placed on a plastic mesh (1 mm pore size) and further located between two ring 135 
shaped silicon adapters with a circular aperture of 0.64 cm2. The silicon adapters with the tissue was placed in a 136 
vertical Ussing/diffusion chamber (Navicyte, Harvard Apparatus, Holliston, MA). The chamber parts in contact with 137 
the silicon adapters had been treated with vacuum grease to avoid edge leakage during the experiment. BSS Plus 138 
supplemented with 10 mM Hepes (pH 7.4) buffer was added to both sides of the chambers; 5 ml in the cassette 139 
mixture experiments and 4 ml in the bevacizumab experiments. Both sides of the chambers were attached to gas 140 
tubing, supplying the tissue with gas (5% CO2, 10% O2, and 85% N2) at a rate of 3-4 bubbles/s. The bubbling 141 
mixed the buffer solution and maintained the pH at 7.4. The chambers were maintained at 37 °C with a heating 142 
block and circulating water bath (Grant Instruments Ltd, Cambridge, England). The chambers were equipped with 143 
electrode caps and glass barrel Ag/AgCl electrodes (NaviCyte Electrodes; Harvard Apparatus) that were 144 
connected to a voltage-current clamp (VCC MC6; Physiologic Instruments, San Diego, CA) for transepithelial 145 
electrical resistance (TER) measurements as described previously 12.   146 
 147 
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Permeability of the cassette mixture drugs was studied in outward and inward directions. The outward direction 148 
mimics vitreous-to-choroid permeation (apical to basolateral), whereas the inward permeation models choroid-to-149 
vitreous distribution (basolateral to apical side). The bevacizumab permeability was studied only in the outward 150 
direction. The permeability experiments were initiated by replacing 500-700 µl of drug solution to the donor side 151 
(cassette mix or bevacizumab). The drug concentrations in the donor side were 20 or 200 µg/ml in the cassette 152 
mix. Bevacizumab concentration in the donor side was 4.4 mg/ml. In the cassette mix study, samples of 500 µl 153 
were withdrawn from the receiver site at 15, 30, 45, 60, 75, 90, 120, 150,180, 210, 240, 270, 300, 330, and 360 154 
min and replaced with blanc buffer. Additionally, samples of 40 µl were withdrawn from the donor side in the 155 
beginning and at the end of the experiment. The samples were stored in -20 °C for later LC-MS/MS analysis. In 156 
the bevacizumab study, samples of 100 µl were withdrawn from the receiver site at 180, 240, 270, 300, 330, 360, 157 
390, and 420 min and replaced with blanc buffer. Samples of 10 µl were withdrawn from the donor side in the 158 
beginning and at the end of the experiment. These samples were stored overnight in + 4 °C and analyzed next 159 
day by ELISA. 160 
 161 
The apparent permeability coefficients (Papp) of the eight small molecular weight drugs and bevacizumab were 162 
calculated (Eq. 1) as:  163 
Papp, RPE-choroid (cm/s) = J / C0                                                Eq.1 164 
 165 
Where J (ng/cm2*s) is the drug flux across the exposed membrane area (A=0.64 cm2) in the linear range and C0 166 
is the initial drug concentration in the donor compartment (ng/cm3). The sink conditions were maintained during 167 
the permeability experiments (i.e. drug concentration in the receiver side was below 10% of the donor side 168 
concentration). 169 
 170 
2.4 Quantitative analyses 171 
 172 
2.4.1 Small molecular drugs  173 
 174 
The concentrations of the small molecular weight drugs in the cassette mix were analyzed with a slightly modified 175 
UPLC-MS/MS technique from previous study 12. Minimum of eight standard curve points and blank control were 176 
used for quantitation of the compounds. Standard curve included all eight analytes and the following four 177 
deuterated internal standards: atenolol-d7, ganciclovir-d5, methotrexate-d3, and lincomycin-d3. The method was 178 
validated by including four quality control samples in three parallel sets. The linearity range varied from 1 to 1000 179 
ng/ml depending of the compound, and limit of quantitation (LOQ) was set to the lowest concentration in the 180 
standard curve for each drug. The linear concentration range for each drug is presented in Supplementary material 181 
(Table 1). 182 
 183 
Liquid chromatography separations were carried out using Waters Acquity UPLC instrument, with the flow through 184 
needle injection system (Waters, MA, USA) coupled with Agilent Poroshell 120 SB-C18 (2.1 x 50 mm, 2.7 µm) 185 
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column (Agilent Technologies, Inc., DE, USA) at 50 C. The mobile phase consisted of 0.1% of formic acid in 186 
ultrapure water (A) and 100% of LC-MS grade acetonitrile (B). The gradient elution started with 2% of B at 0-1 min 187 
and continued with 2-95% of B at 1-5 min. Total run time was 9.5 min including flush and equilibration of the 188 
column. The flow-rate was set to 0.3 ml/min and injection volume to 0.3 µl. After every sample two wash injections, 189 
composed of a mixture of ultrapure water and isopropanol including 0.1 % formic acid, were performed to prevent 190 
any carry over. 191 
Mass spectrometry measurements were carried out using a Waters Xevo triple quadrupole mass spectrometer 192 
(TQ-S) equipped with an ESI source (Waters) operated in positive ionization mode. The optimal source parameters 193 
were: capillary voltage 3.5 V, cone voltage 2 V, source temperature 150 °C, desolvation temperature 500 °C. 194 
Nitrogen (Aga, Helsinki, Finland) was used as desolvation gas (800 L h−1) and cone gas (150 L h−1), argon (Aga, 195 
Helsinki, Finland) was used as collision gas (0.15 ml/min). The multiple reaction monitoring (MRM) mode was 196 
used for quantification. The precursor and fragment ions of the small molecular weight drugs and the internal 197 
standards (with their collision energies) are presented in Supplementary material (Table 2). The resulting data was 198 
analyzed with Waters MassLynx software V4.1 199 
 200 
2.4.2 Bevacizumab 201 
 202 
The concentration of bevacizumab was analyzed with a BioSim™ Bevacizumab (Avastin®) (Human) ELISA Kit 203 
(E4373-100, BioVision, CA, USA) using manufacturer’s protocol.  The standards were prepared in BSS Plus (10 204 
mM Hepes) buffer. The reliability of the method was checked by preparing standards also to the manufacturer’s 205 
Assay Buffer. 206 
 207 
Stability of bevacizumab was analyzed in different conditions for 6 hours to assure protein stability in the 208 
permeability studies (Table 2). Stability of bevacizumab was analyze with ELISA assays. 209 
 210 
Table 2. Conditions of bevacizumab stability studies. 211 
Concentration Buffer Temperature Gas* Comments 
5.7 mg/ml BSS Plus (10 mM Hepes) 37 °C yes Permeability assay conditions 
3 mg/ml BSS Plus (10 mM Hepes) 37 °C no  
3 mg/ml BSS Plus (10 mM Hepes) 25 °C no  
3 mg/ml 0.9% NaCl 25 °C no 48 h stability guaranteed by 
the manufacturer 
 *5% CO2, 10% O2, and 85% N2 gas 212 
 213 
 214 
 215 
 216 
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2.5 Calculation of RPE clearance 217 
 218 
Contribution of RPE as elimination route from the vitreous or as a distribution route from the systemic blood 219 
circulation was estimated by calculating clearance via RPE (CLRPE; ml/h) (Eq. 2 and Eq. 3):  220 
 221 
outward CLRPE = outward Papp, RPE-choroid x SRPE  vitreous-to-choroid   Eq.2 222 
inward CLRPE = inward Papp, RPE-choroid x SRPE  choroid-to-vitreous   Eq.3 223 
 224 
where Papp, RPE is the drug permeability (cm/s) in the RPE-choroid and SRPE is the surface area of the rabbit RPE 225 
(5.2 cm2) 13.  226 
 227 
2.6. Simulations on ocular drug entry through the RPE  228 
 229 
The simulations were performed using the modified model from Vellonen et al., (2016)10 (Fig. 1). In the model drug 230 
transfer between systemic blood circulation and vitreal cavity was assumed to be dictated by the distribution 231 
clearance between the blood circulation and eye (CLBV). The clearance for drug elimination from the vitreous 232 
(CLIVT) for ciprofloxacin, fluconazole and methotrexate were obtained from in vivo rabbit studies as calculated in 233 
del Amo et al (2015). The CLBV was obtained 1) by assuming drug entry only via the RPE using inward CLRPE 234 
(Equation 3) or 2) by assuming all routes of entry (CLIVT) into the vitreous. The drug may enter the vitreous from 235 
the systemic blood circulation across the BRB and BAB. Intravitreal drug concentrations were simulated for 236 
ciprofloxacin, methotrexate, and fluconazole using RPE entry or total entry scenarios. Only free drug was assumed 237 
to permeate across the blood ocular barriers. The fractions of free drug and protein bound drug in the plasma and 238 
vitreous were obtained from the literature 10,14. A more detailed structure of the model, including equations and 239 
model parameters can be found from Supplementary material (Fig. 1 and Table 3). 240 
 241 
 242 
 243 
 244 
 245 
 246 
 247 
 248 
 249 
 250 
 251 
 252 
Figure 1. The compartmental model used for simulating intravitreal drug concentration after systemic drug 253 
administration, adapted to the calculated inward RPE clearance values.  254 
 255 
 256 
 257 
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3. Results 258 
 259 
3.1 Drug permeability 260 
 261 
Overall drug permeabilities in the ex vivo RPE-choroid experiments ranged over 3 orders of magnitude (from 262 
ketorolac and voriconazole to bevacizumab) indicating that the membrane was tight and intact (Table 3). The 263 
integrity of the RPE-choroid was also confirmed at the beginning of the experiments by transepithelial resistance 264 
(TER) measurements, which was 102 ± 55 Ω x cm2 (n=22). 265 
 266 
Among small molecules the range of permeability values was 13-15 fold for outward and inward permeation, also 267 
suggesting proper barrier properties (Table 3). Hydrophilic aztreonam (LogD7.4: – 4.32) had 5-times lower 268 
permeability (4–5 x 10-6 cm/s) than lipophilic voriconazole (LogD7.4: 1.21; 20–25 x 10-6 cm/s). The results of 269 
quinidine are not reported, because the mass balance was incomplete. Outward and inward permeability values 270 
in the isolated bovine RPE-choroid were in the same range for 5 compounds (Table 3, Fig. 2). Ciprofloxacin and 271 
ketorolac showed preferred directionality for outward permeation (Table 3; Fig. 1).  272 
 273 
Bevacizumab (molecular weight 149 kDa) had 100- to 200-fold lower permeability than hydrophilic small molecules 274 
(aztreonam, methotrexate) and 2000 times slower outward permeation than ketorolac. The stability experiments 275 
showed that bevacizumab was stable in the permeability studies (results in Supplementary material, Table 4).  276 
 277 
Table 3. Permeability data from the experiments with isolated RPE-choroid tissues.  278 
Drug LogD7.4* Molecular 
weight  
Outward Papp, RPE-choroid 
x 10 -6  cm/s 
Inward Papp, RPE-choroid 
x 10 -6  cm/s 
Outward/Inward  
Papp, RPE-choroid 
ratio** 
Aztreonam – 4.32 435.4 5.37 ± 5.19           (n= 8) 4.47 ± 2.62        (n=  9) 1.2 
Ciprofloxacin – 0.29 331.3 9.52 ± 5.28           (n= 7) 1.43 ± 0.77        (n=  8) 6.7 
Fluconazole 0.45 306.3 15.64 ± 4.66         (n= 8) 12.95 ± 2.69      (n=  9) 1.2 
Ganciclovir – 1.61 255.2 9.70 ± 7.90           (n= 8) 6.49 ± 3.97        (n=  9) 1.5 
Ketorolac – 0.34 255.3 69.21 ± 31.9         (n= 8) 4.78 ± 3.99        (n=  9) 14.5 
Methotrexate – 5.1 454.4 9.39 ± 2.74           (n= 8) 4.54 ± 2.99        (n=  8) 2.1 
Voriconazole 1.21 349.3 25.00 ± 6.12         (n= 8) 21.02 ± 4.21      (n=  9) 1.2 
Bevacizumab  149 000 0.035 ± 0.020       (n= 4)   
*LogD7.4 values are computational (ACDlabs® software, version 12; Advanced Chemistry Development, Inc., 279 
Toronto, Canada) 280 
** The outward/inward ratio is calculated based on the mean values of outward and inward Papp, RPE-choroid 281 
 282 
 283 
 284 
 285 
 286 
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 288 
 289 
 290 
 291 
 292 
 293 
 294 
 295 
 296 
 297 
 298 
 299 
 300 
 301 
 302 
 303 
 304 
 305 
 306 
 307 
 308 
 309 
 310 
 311 
 312 
Figure 2. The outward versus inward RPE-choroid permeability of the cassette dose drugs (n= 7-9). The dashed 313 
line represents identical permeabilities without directionality. The dotted lines show the situations in which inward 314 
Papp, RPE-choroid  is either 3-fold lower or 3-fold higher than outward Papp, RPE-choroid. 315 
 316 
 317 
3.2 Estimated drug clearance across the RPE 318 
 319 
The outward permeability (vitreous-to-choroid) values were used to calculate drug clearance across the RPE-320 
choroid (outward CLRPE) (Table 4). These values were compared to in vivo intravitreal clearance (CLIVT) values in 321 
the rabbit eye 5 (Table 4; Fig. 3). For most drugs outward CLRPE values were within 2.6 fold range from CLIVT values 322 
(Fig. 3, Table 4). The high outward permeability of ketorolac resulted in an outward CLRPE value that was five times 323 
higher than the CLIVT. Low outward permeability of bevacizumab resulted in low CLRPE (about 0.035 x CLIVT).  324 
 325 
Table 4. The intravitreal clearance (CLIVT) in rabbit 5 and the calculated (Eq. 2) outward RPE-choroid clearance 326 
(CLRPE) of the cassette dose drugs and bevacizumab.  327 
Drug CLIVT (ml/h) in rabbit5 outward CLRPE (ml/h) CLIVT/CLRPE (CLRPE /CLIVT ) x 100% 
Aztreonam 0.125 0.101 ± 0.097 1.2 81 
Ciprofloxacin 0.336 0.178 ± 0.099 1.9 53 
Fluconazole 0.753 0.293 ± 0.087 2.6 39 
Ganciclovir 0.153 0.182 ± 0.148 0.84 119 
Ketorolac 0.283 1.296 ± 0.597 0.22 458 
Methotrexate 0.197 0.176 ± 0.051 1.1 89 
Voriconazole 0.421 0.468 ± 0.115 0.90 111 
Bevacizumab 0.019 0.000657 ± 0.000365 29 3.5 
 328 
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 330 
 331 
 332 
 333 
 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
 345 
 346 
 347 
 348 
 349 
 350 
 351 
 352 
 353 
 354 
Figure 3. Experimental intravitreal drug clearance in rabbits in vivo (CLIVT) versus calculated outward RPE 355 
clearance (CLRPE) from this study. The dashed line represents identical values for CLRPE and CLIVT.  The dotted 356 
lines show the situations in which outward CLRPE is either 3-fold lower or 3-fold higher than CLIVT.  357 
 358 
 359 
3.3. Simulations on the RPE contribution in ocular entry of systemic drugs 360 
 361 
Contribution of the RPE as the ocular entry route from systemic blood circulation was simulated by comparing two 362 
situations: CLBV equals the inward CLRPE (entry only via RPE) or CLIVT (entry via all possible routes, across the 363 
BRB and BAB). In both cases, drug elimination from the vitreous was simulated using the in vivo intravitreal 364 
clearance (CLIVT) values (including all routes of elimination) instead of the calculated outward clearance values 365 
across the RPE (outward CLRPE). Table 5 shows the simulated approximate AUC values for ciprofloxacin, 366 
methotrexate, and fluconazole. The contribution of RPE as the route of entry varies among the compounds: 367 
ciprofloxacin 8%, methotrexate 43% and fluconazole 32%. Since these three compounds show higher outward 368 
than inward permeability in the RPE, it seems that in many cases the RPE has more important contribution on 369 
intravitreal drug elimination than on the drug distribution from the blood stream into the vitreous.    370 
 371 
 372 
 373 
 374 
 375 
 376 
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Table 5. Simulated AUC values in the vitreous after systemic delivery of ciprofloxacin 100 mg, methotrexate 12.5 377 
mg and fluconazole 50 mg, assuming drug distribution from the blood circulation to the vitreous (CLBV) equal to 378 
inward CLRPE (1) or equal to CLIVT (2). 379 
Ocular entry route CLBV 
AUC (µg x h/ml) in vitreous 
Ciprofloxacin  Methotrexate  Fluconazole 
1. Only RPE Inward CLRPE* 1.56 15.89 19.85 
2. All routes CLIVT  19.60 36.85 61.65 
* Inward CLRPE values for ciprofloxacin (0.0268 ml/h), methotrexate (0.0850 ml/h) and, fluconazole (0.242ml/h) 380 
were based on the experimental values. Inward CLRPE values were based on equation 3: inward CLRPE = inward 381 
Papp, RPE-choroid x SRPE  382 
 383 
 384 
4. Discussion 385 
 386 
Intravitreal injection is the most commonly used route of drug administration for  the treatment of the posterior eye 387 
segment 3. The typical range of intravitreal clearance values for small and large molecular weight compounds have 388 
been earlier defined and their routes of elimination have been proposed 5. However, only permeability studies can 389 
give a clear insight of the route of elimination of these compounds from the vitreous. Likewise, drug entry from the 390 
blood circulation into the vitreous has been characterized and modeled 10, but the role of RPE in ocular drug entry 391 
has not been explored.  392 
 393 
Based on the results, most of the small molecular weight drugs showed a similar outward CLRPE and CLIVT, which 394 
illustrates that the RPE is their main elimination route from the vitreous after intravitreal injection. Mostly the CLIVT 395 
values were slightly higher than the calculated outward CLRPE values. This is most probably due to the presence 396 
of other elimination routes in vivo, such as aqueous humour outflow, ciliary body, and iris. On the contrary, the 397 
outward CLRPE for bevacizumab (149 kDa) was only 3.5% of its intravitreal clearance, which is in line with the 398 
conclusions drawn by del Amo et al., (2017), stating that only 3-20% of macromolecules (MW 4-80 kDa) are 399 
eliminated across the RPE. Hutton-Smith et al., (2017) reached similar conclusions with a three-compartment 400 
semi-mechanistic model for estimating retinal permeability (RPE and inner limiting membrane) of IgG, IgG null, Fc 401 
and Fab fragment. They concluded that 13-18% of these are eliminated across the RPE and the rest via other 402 
routes.   403 
 404 
Rabbit is the most commonly used animal model in ocular in vivo pharmacokinetic studies and therefore intravitreal 405 
clearance data is mainly available from this specie. However, bovine eyes were chosen as the animal model for 406 
permeability studies due to easy isolation of the RPE-choroid from bovine eyes. The RPE was isolated together 407 
or partly with the underlying choroid, but choroid is a leaky layer (TER ≈ 9 Ω x cm2) that does not restrict the 408 
permeation of solutes 15. Most of the small molecular weight drugs (255 – 454 Da), excluding ciprofloxacin and 409 
ketorolac, showed similar permeability in outward and inward directions (Papp, RPE-choroid = 10-6 – 10-5 cm/s), which 410 
is an indication of passive permeability. Bevacizumab (149 kDa) had low outward permeability of 2-3 orders of 411 
magnitude lower (10-8 cm/s) than the small molecular weight drugs. To our knowledge this is the first time 412 
experimental values of RPE permeability is been presented for the therapeutic drug, bevacizumab (Avastin ®). 413 
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Quinidine was included in the original drug mixture, but the mass balance of quinidine was incomplete, suggesting 414 
accumulation to the cell components, such as melanosomes. The choroid and RPE are enriched in melanin, and 415 
associated with prolonged retention of quinidine in the melanosomes 16,17.  416 
 417 
Outward Papp, RPE-choroid of ciprofloxacin and ketorolac were 6 and 14 times higher than their inward permeability in 418 
the bovine RPE-choroid, respectively. The directional permeability could be explained by the presence of active 419 
transporters. RPE is known to express both influx and efflux transporters on both sides of the membrane 7,9. 420 
Ciprofloxacin had particularly low permeability in the inward direction, compared to the other small molecular 421 
weight drugs. This might be due to binding of ciprofloxacin to efflux transporter(s) in the RPE 3,18. For example, 422 
MRP4 is known to transport ciprofloxacin and it is present in the human RPE 7,19.  Ketorolac had much higher 423 
outward permeability than the other small molecular weight drugs, while its inward permeability was in the same 424 
range with the other drugs. This may be due to influx transporter activity on the vitreal side of the RPE. For instance 425 
OAT2 is present in human RPE 7 and it is capable of transporting ketorolac 20. Additionally, when using a mixture 426 
of drug molecules there is a possibility for transporter related interactions. Another competing drug may interfere 427 
with the permeability of a transporter dependent drug molecule.  In any case, only sparse information is available 428 
of the expression and activity of transporters in the bovine RPE 9,21. Available data suggest that the transporters 429 
may only have a modest role in the pharmacokinetics of the RPE 9.  430 
 431 
The role of RPE in drug distribution from the systemic blood circulation into the vitreous was simulated with a 432 
modified model of Vellonen et al., (2016)10. The simulations showed that the RPE permeation contributes to the 433 
vitreal drug concentrations as a route of entry, but it is not necessarily a dominating one (Table 5). This could be 434 
explained by the presence of efflux transporters at the choroidal side of the RPE that may reduce the inward 435 
permeability of the drug. On the other hand, other routes of drug entry from blood circulation, such as at the BAB 436 
the nonpigmented ciliary epithelium and fenestrated vessels in the ciliary processes, could play significant role in 437 
the inward drug permeation. The nonpigmented ciliary epithelium has similar surface area as the RPE (1.4 x 438 
difference in humans 3). Thus, BAB may play an important role in the distribution of small molecular weight drugs, 439 
but its pharmacokinetic role is poorly known.  440 
 441 
The information on RPE permeability is useful in developing new ocular drugs and drug delivery systems. 442 
Information on barrier permeability will be useful in building physiologically based pharmacokinetic models and 443 
finite element models that will facilitate ocular drug development 22–25.  444 
 445 
Conclusions 446 
 447 
Bidirectional permeability studies with excised RPE-choroid specimens were carried out with small molecular 448 
weight drugs and bevacizumab. The permeability values spanned over a range of three orders of magnitude. 449 
Permeability values were further used to calculate clearance values for drug transfer across the RPE from and 450 
into the eye. It seems that the RPE is the main elimination route for small molecular weight drugs from the vitreous, 451 
13 
 
and efficiently blocks permeation of macromolecules, such as bevacizumab. For systemic drugs, the RPE 452 
contribute in drug distribution to the eye, but it is not the only route.  453 
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